Edward Van Wezel

Edward Van Wezel has over 20 years of experience in the industry. Edward began their career in 1997 as a Project Manager at Johnson & Johnson. In 2001, they became the Managing Director of Macrozyme BV. In 2006, they founded and became the Managing Partner of BGV (BioGeneration Ventures). In 2013, they became the Founding Investor and Member of the Supervisory Board of Acerta Pharma B.V. In 2017, they became the Board Director of Escalier Biosciences, Scenic Biotech, and AZAFAROS B.V. In 2018, they joined Confo Therapeutics as a Board Director. In 2020, they became the Board Director of duallyx and the Director of TigaTx.

Edward Van Wezel studied Chemistry at Utrecht University and Biochemical process technology at Delft University of Technology.